These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000767-10 A Phase I/II, Single Center, Partially Observer-Blind, Controlled, Randomized Study to Explore Safety and Immunogenicity in Healthy Adult Subjects who Receive Either One Dose of Chiron Combined MenC-H... bad-data
Reported results 2004-001896-21 A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Mo... 2006-10-12 due-trials
Reported results 2004-001952-35 A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Agrippal™ S1, Influva... 2005-09-15 due-trials
Reported results 2004-003616-37 M48P3: A phase IV, randomized, controlled, single-blind, multi-center study in children to evaluate the safety, tolerability and immunogenicity of two TBE vaccines administered according to two differ... 2006-07-19 due-trials
Reported results 2004-004962-33 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization with Chiron Meningococcal C Conjugate Vaccine Menjugate® Administ... 2005-11-15 due-trials
Completed, but no date, and reported results 2004-005150-31 A Phase IV, Multi-Center, Controlled, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Meningococcal C Conjugate Vaccine Menjugate® when Given as First, Third or Four... bad-data
Reported results 2005-000430-20 A phase III, multicenter, uncontrolled, open label study to demonstrate safety, tolerability and immunogenicity of the Chiron Behring preservative free inactivated split influenza vaccine using the st... 2005-06-02 due-trials
Completed, but no date, and reported results 2005-000621-38 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD? Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2005-200... bad-data
Completed, but no date, and reported results 2005-000622-23 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL? S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, when Administered... bad-data
Reported results 2005-000659-14 A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2005-2006, when administered to... 2005-05-09 due-trials
Reported results 2005-001349-40 A Multicentre, Randomised, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI) 2008-05-06 due-trials
Reported results 2005-002257-47 A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of Trivalent Subunit Influenza ... 2006-04-18 due-trials
Reported results 2005-003772-37 A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects 2009-03-12 due-trials
Reported results 2005-004459-36 A phase IV, randomized, open-label, multi-center study in adults: Evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in s... 2006-09-05 due-trials
Completed, but no date, and reported results 2005-005519-12 A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellula... bad-data
Completed, but no date, and reported results 2005-005871-14 A Phase II, Randomized, Controlled, Observer-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two FLUAD-like Surface Antigen Adjuvanted... bad-data
Completed, but no date, and reported results 2006-000438-11 A Phase III, Multicenter, Uncontrolled, Open-label study to evaluate Safety and Immunogenicity of Begrivac, preservative free inactivated Split Influenza Vaccine, using the Strain Composition 2006/200... bad-data
Completed, but no date, and reported results 2006-000609-43 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, when Administered ... bad-data
Completed, but no date, and reported results 2006-000610-20 A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2006-2007... bad-data
Reported results 2006-000732-28 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C saccharide component of Chiron’s Meningococcal C Conjugate Vaccine (Menjugate®) Administered to ... 2006-08-10 due-trials
Reported results 2006-000787-88 A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, when Administered to... 2006-11-16 due-trials
Completed, but no date, and reported results 2006-004063-66 A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD-li... bad-data

Related organisations

Over time organisations can merge, or split.

We think Chiron is now effectively part of Novartis.